Featured event

Integrium, LLC Executives to Attend RESI Conference, San Francisco

By: Emily MacHale

Tustin, CA – Integrium, LLC Executives will be in San Francisco during the Redefining Early Stage Investments (RESI) Conference on January 9th, 2018 at Marines’ Memorial Club and Hotel. Integrium key Executives are eager to attend the conference to connect with over 1,000 industry folks in therapeutic, diagnostic, medical device, and investor companies around the globe.

Looking to meet with various types of organizations, Integrium typically engages in collaboration with startups and investors to discuss new business ventures and ways to work in partnerships. RESI attendees are encouraged to connect with Integrium for a brief introduction meeting during the conference and can request meeting time-slots by contacting Mike Loftus, Executive Director of Business Development to schedule: Mike.Loftus@integrium.com.


Integrium, LLC Executives to Attend 10th Annual LD Micro Main Event in Los Angeles, CA

By: Emily MacHale

Tustin, CA – Integrium, LLC Executives will be attending the 10th Annual LD Micro Main Event in Los Angeles, CA starting on the evening of December 4th through 7th, 2017. The conference brings together micro-cap companies looking to collaborate on ideas and recent findings in the industry, as well as old and new companies looking to strategize.

Integrium Executives value the opportunity that is provided at the LD Micro event because of the exposure they have to various micro-cap companies that have joined the group. With access to keynote speakers, panel discussions, and highlevel presentations, the event is the perfect opportunity for Integrium to make and advance relationships within the micro-cap community.


Join Integrium, LLC in San Francisco at the Microbiome Breakfast Round-Table: J.P. Morgan

By: Emily MacHale

During J.P. Morgan 36th Annual Healthcare Conference
Hosted by Integrium, LLC and EisnerAmper

The Microbiome breakfast will allow networking between Microbiome Companies
and Venture Capitalists who are active in the Microbiome space:

The following presentations and topics will be discussed:

  • Clinical lessons learned with respect to gut, dermatology, and metabolic microbiome studies.
  • Unique exit strategies with respect to Microbiome companies and how they differ from therapeutic companies.
  • A Venture Capitalist perspective on how they view Microbiome therapeutics from 510(k).
  • View or perspective from Microbiome sponsors on the unique challenges they see in the industry.

Meet the Experts and Learn Industry Secrets

Join Integrium, LLC and EisnerAmper Executives at our breakfast round-table during the week of the 2018 J.P. Morgan 36th Annual Healthcare Conference.

Integrium will be sharing their expertise within microbiome clinical trials, fecal sample collection lessons learned, tips to shorten the path to commercialization, exit strategies for microbiome companies, and alternative financing solutions. Integrium has worked on a solid number of Microbiome-related trials and has an extensive database of 2,500+ pre-screened patients whom are interested in microbiome skin and stool-based studies.

EisnerAmper, who has partnered with Integrium in the past on a number of events, will be covering a broad range of topics such as impact of tax reform on life sciences companies, the current life sciences financing environment, and beyond.

A Time To Collaborate and Connect

Come ready to discuss, enjoy a light breakfast with coffee, and develop relationships with like-minded industry folks in the microbiome, biotech, medical device, diagnostic, and financial sectors.

Who: Microbiome Companies, Microbiome Venture Capital and Private Equity
When: January 10th, 2018
Where: EisnerAmper: 1 Market St # 620, San Francisco, CA 94105
Time: 8:00 - 10:00 AM PST


Integrium, LLC Executives to Attend American Association of Pharmaceutical Scientists

By: Emily MacHale

Tustin, CA – Integrium, LLC Executives will be attending the American Association of Pharmaceutical Scientists (AAPS) in San Diego on November 12-15, 2017. Taking place at the San Diego Convention Center, Integrium is looking forward to connecting with industry folks and learning more about patient-centric innovations and opportunities.

The chance to be able to hear from top speakers, keynote presentations, and more is valuable to Integrium and their current initiatives in the biotechnology ecosystem. This conference provides the opportunity to connect with CEOs, scientists and clinical partners that are advancing Generic, 505b2 and other healthcare initiatives while finding solutions to improve patient-centric goals. Integrium welcomes CEOs, scientists and clinical partners to join them in finding potential ways to collaborate and develop partnerships for current and future opportunities.

Integrium will be available for meetings throughout the event and encourages guests reach out to Emily MacHale, Associate Director of Marketing & Research at Emily.MacHale@integrium.com for any meeting requests.


Integrium, LLC to Discuss Alternative Financing Solutions for Biotech during J.P. Morgan 36th Annual Healthcare Conference Week

By: Emily MacHale

Tustin, CA – Integrium, LLC Executives will be in San Francisco during the J.P. Morgan 36th Annual Healthcare Conference on January 8-11, 2018. Being in San Francisco during the conference over the past 7 years, Integrium is able to continue connecting with biotech, medical device, and diagnostic companies, while building new relationships and cross-pollinating a wide span of industry sectors.

The JPM Conference is expecting to host over 400 public and private companies, in addition to more than 8,000 guests. Being the largest healthcare investment conference in the industry, Integrium values the opportunity to connect with investors and like-minded folks looking to collaborate and develop strategic partnerships.

Integrium will be available for meetings January 8-11, 2018 and encourages guests to reach out to Emily MacHale, Associate Director of Marketing & Research at Emily.MacHale@integrium.com for any meeting requests.


Integrium, LLC Executives to Attend 5th Microbiome R&D and Business Collaboration Forum: USA

By: Emily MacHale

Tustin, CA – Integrium Executives are attending the 5th Microbiome R&D and Business Collaboration Forum in San Diego on November 2-3, 2017; with the collaboration of the 2nd Probiotics Congress: USA. Integrium Executives are excited to network and share ideas with the projected over 400 attendees and 70 speakers that will be involved in roundtables, panel discussions, networking events, and more. More specifically, Integrium is looking forward to learning more about the innovative opportunities involving the human microbiome: the gut, skin, oral, genetic disease states and beyond.

Integrium is heavily invested in the microbiome space, currently conducting various dermatology and gut microbiome studies. In addition, Integrium’s clinical Phase I - IV unit (Orange County Research Center) has thousands of pre-screened healthy volunteers that participate (or want to participate) in upcoming fecal sampling studies. Having better knowledge of the microbiome is important to understanding numerous existing genetic diseases. Many genetic diseases require their own unique approach, and grasping the ins and outs of the microbiome can impact the way we tackle these innovative drug development goals.

Actively participating in the 5th Microbiome R&D and Business Collaboration Forum allows Integrium to broaden goals and initiatives for microbiome-based disease cures, provides opportunity to dip into recent findings, and to stay in touch with industry trends. With that, investors are able to join and find potential partnerships with early-stage biotechs and start-ups.

Integrium is available for meetings all day on November 2, 2017 and encourages guests reach out to Emily MacHale, Associate Director of Marketing & Research at Emily.MacHale@integrium.com for any meeting requests.


Integrium, LLC to Attend 2017 Microbiome Drug Development Summit in Boston, MA

Tustin, CA – Integrium Executives will be in Boston for the 2017 Microbiome Drug Development Summit on June 27-29. Intrigued by the summits' information-filled approach, Integrium Executives are looking forward to gaining access to microbiome clinical information to broaden the future in this rapidly changing therapeutic area.

The summit consists of a wide range of topics discussed around microbiome drug development and the future of clinical advancement. Being that the microbiome plays a huge role in our overall health, the need for finding discoveries to help cure diseases is never-ending. The Microbiome Drug Development Summit allows key industry leaders to collaborate with like-minded people and companies that share a common goal and overall advance microbiome medicine.

“Although we have been conducting Microbiome clinical trials for years, we always want to learn more about the microbiome and how to best go about designing safe and effective clinical trials; which gives Integrium the knowledge and understanding to tackle these new, cutting-edge opportunities,” mentioned Mike Loftus, Executive Director of Business Development. Hearing from the clinical side of the microbiome field helps Integrium target their microbiome services to the right companies that are in the market for these unique set of skills.

Integrium Executives are looking forward to being involved in workshops and hearing from speakers that will discuss improving preclinical models for microbiome drug discovery, key factors to designing safe and effective clinical trials, raising investments to advance therapeutic efforts, and more. Having access to the latest information in the microbiome field will provide Integrium with the knowledge to tackle the challenges that exist in the pharmaceutical industry today.

Integrium Executives will be taking meetings throughout the summit and encourage guests to schedule meeting requests with Emily MacHale at Emily.MacHale@integrium.com. We look forward to seeing you there!


Integrium, LLC to Attend RESI San Diego 2017

By: Emily MacHale

Tustin, CA – Integrium, LLC announced they will be attending RESI San Diego 2017 on June 19, 2017. RESI allows life science companies to connect with investors that come from backgrounds related to Virtual Pharma, Angels, Venture Philanthropy, Patient Groups, Corporate Development, and more. Encouraging in person meetings with pharma companies or service providers and investors, RESI is a place for developing new connections, continuing business relationships, and overall finding capital.

Integrium Executives have always benefited from facilitating meetings during the fast-paced day at RESI. As active members in the life science community, Integrium is able to share the various funding options that are available within their organization, clinical trial expertise in a number of therapeutic areas, and their platform for CRO and
investor success.

Integrium is available for meetings throughout the day on Monday, June 19, and welcomes all life science companies, investors, and service providers. To schedule a meeting, please contact Emily MacHale at Emily.MacHale@integrium.com or connect with Mike Loftus, Executive Director of Business Development via the RESI partnering system: http://resi-sd17.meeting-mojo.com/. If the partnering system is unavailable to you, please reach out to Mike directly at mike.loftus@integrium.com


Integrium, LLC to Attend 2017 BIO International Convention in San Diego, CA

By: Emily MacHale

Tustin, CA – Integrium, LLC announced they will be attending the 2017 BIO International Convention located in San Diego, CA on June 19-22. Integrium is looking forward to joining other industry leaders and pharmaceutical companies to fulfill networking goals and potential partnerships. As with previous years, Integrium will not only be forming relationships, but will be educating themselves on the hot topics in biotechnology, healthcare, and beyond.

BIO is home to numerous networking meetings, companies joining together to find ways to collaborate, and organizations showcasing their objectives and pipeline. With a partnering system that allows attendees to independently register and schedule their own meetings, more than 35,000+ meetings were scheduled for 2016 between 3,500 companies and in only 3.5 days, leading BIO 2017 to be one for the books. Integrium is heavily involved in the partnering system and thoroughly enjoys learning about each company’s goals and initiatives.

Integrium Executives will be taking meetings throughout BIO and encourage guests to schedule meeting requests with Mike Loftus, Executive Director of Business Development and other companies attending BIO via the BIO partnering system http://convention.bio.org/partner/. If you have trouble accessing the link please contact Mike Loftus at Mike.Loftus@integrium.com or Emily MacHale at Emily.MacHale@integrium.com.


Integrium, LLC to Attend Alliance for Regenerative Medicine 5th
Annual Cell & Gene Investor Day in Boston!

By: Emily MacHale

Tustin, CA – Executives of the Integrium team will be in Boston during the Alliance for Regenerative Medicine 5th Annual Cell & Gene Investor Day on April 27th, 2017. On this one day filled with opportunity for investors to collaborate with advanced therapeutic biotechs, Integrium seeks to meet and gain insight on how they can be of help to numerous life science experts.

Hearing from industry leaders helps Integrium with effectively positioning themselves in the biotech marketplace regarding investment and financing opportunities. Meanwhile, Integrium can understand the needs of biotechs and what they require during their search for an investor. With over 350 attendees and more than 175 of them active investors and analysts, Integrium is successfully able to meet with clinical experts and develop one-on-one relationships.

Integrium helps micro-cap, small-cap, and small private biotechs attain clinical data so they can raise their next round of capital. Integrium typically invests in two to four private biotechs each year and have the ability and goal to take on 3 more investments in 2017. Integrium’s areas of therapeutic focus include Cardiovascular, Metabolic, Renal, Inflammatory, Dermatology, Wound Healing, Gene Therapy, and Orphan Diseases. Secondary specialties include Schedule 2 drugs and Oncology.


Integrium, LLC Executives to Attend RESI on MaRS 2017!

By: Emily MacHale

Tustin, CA – Integrium, LLC Executives will attend RESI on MaRS 2017 in Toronto, Canada on April 4, 2017. Hosted each year, RESI is notorious for providing meetings for hungry fundraisers and allowing them to connect with eager life science investors. Guests will also be able to hear from investors and their firsthand experience with the investing process and the best tactics for qualifying candidates.

RESI gives Integrium Executives the chance to market their products and services to fundraisers in the life sciences field in hopes to find ways to collaborate on various levels. Through powerful synergy discussions and room for networking, Integrium Executives are always able to create new relationships with biotechs, medical device companies, investors, and more.

Integrium Executives will be available for meetings at various times throughout RESI. Details are upon meeting request. To reserve a timeslot to meet with Integrium, click below or contact Emily MacHale at emily.machale@integrium.com.

Click here to reserve a meeting


Integrium, LLC Executives to Attend 2017 MassBio Annual Meeting!

By: Emily MacHale

Tustin, CA – Integrium, LLC Executives are attending the 2017 MassBio Annual Meeting in Boston, MA on March 30 – 31, 2017. Each year, the Integrium team is happy to be a part of the fast-paced program the Massachusetts Life Sciences industry offers.

“We are always excited to watch the Massachusetts biotechnology ecosystem engage in keynote presentations, discussions, workshops, networking meetings, and more,” states Michael Loftus, Executive Director of Business Development.

With the number of topics the meeting provides, Integrium especially looks forward to discussions around biotechs funding and emerging markets. As Integrium helps biotechnology, medical device, and diagnostic companies attain clinical data to raise their next round of capital, learning more about the funding industry is a major benefit to Integrium Executives. It is always a pleasure learning from industry experts, keynote speakers, and special guests on their view of our everchanging biotech ecosystem.

Integrium Executives will be available for meetings throughout MassBio at varying times and locations. Details are upon meeting request. To reserve a timeslot to meet with Integrium, click to register below or contact Emily MacHale at emily.machale@integrium.com.

Click to Register


Integrium, LLC Executives to Attend DCAT Week 2017!

By: Emily MacHale

Tustin, CA – Members of the Integrium Executive Management Team will be attending DCAT Week 2017 in New York City on March 20th through 23rd. DCAT Week 2017 is different from previous years because of the improvements and changes to many of the meeting spaces, networking events, venues, and more. Integrium Executives look forward to DCAT Week each year and are especially excited to see the additions to the program this year.

Throughout a full week of networking events, business seminars, and dinner receptions, Integrium Executives use this time to learn more about the current pharmaceutical market and ways to advance business development and investment techniques. Specifically, Integrium looks forward to enhancing their knowledge in the generics pharmaceutical market within leading therapeutic areas. Partnership seminars are also of extreme value to Integrium as they are constantly looking to develop new relationships with biotechs, investors, consultants, and beyond to expand and meet business needs.

Integrium will be available for meetings throughout DCAT Week 2017 at varying times and locations. Details are upon meeting request. To reserve a timeslot to meet with Integrium, click to register below or contact Emily MacHale at emily.machale@integrium.com.

Click to Register


Integrium, LLC Executives to Attend 2017 American Academy of Dermatology Annual Meeting.

Tustin, CA - Integrium, LLC Executives will be attending the American Academy of Dermatology (AAD) Annual Meeting on Friday, March 3rd, 2017 in Orlando, FL. Bringing together dermatology companies across the map each year, Integrium finds AAD Annual Meeting to be an important time to connect with key opinion leaders to discover new trends and news in the dermatology arena.

Taking part in each session led by industry experts provides guests with the knowledge to offer their customers, patients, and beyond with the information needed to be successful within the dermatology sector. The program offers a wide variety of engaging sessions and meetings that are extremely useful to Integrium in their journey to expanding their dermatological therapeutic experience.

Integrium, LLC will be available for meetings on Friday, March 3rd, 2017 at the Orange County Convention Center - West Building. To reserve a time slot to meet with Integrium, register below!

Click to Register


Integrium, LLC to Attend

Why Invest in Philadelphia Now?"
of Life Sciences Collaborative

lifeTustin, CA - Integrium, LLC and Life Sciences Collaborative Executives will be in attendance at Why Invest in Philadelphia Now? Converting Risk Capital to Success Stories on March 7, 2017.

Agenda

Life Sciences Collaborative will host a panel of discussions during their March 2017 event. Topics will include: how to hold an effective meeting, translating good science into a return on investment, investment troubles within the life sciences community, challenges related to different levels of investments, and more.

Panelists include C-Level folks from a wide variety of biotechs and life science companies. They will touch on ways life science entrepreneurs can become more active in the Philadelphia metro area with raising capital, obtaining seed money, acquiring funding, and beyond.

Interested in attending? Register!


Integrium Executives will be in Orlando during

the 2017 GPhA Annual Meeting

Looking to expand your network in the biotech, medical device or
diagnostics field? Secure your spot to meet with us today!

What?

Integrium Executives will be in Orlando during the 2017 GPhA Annual Meeting. We are eager and excited to see friends and discover new relationships in the Generic / Biosimilars / 505(b)(2) industry.

Where?

4040 Central Florida Pkwy,
Orlando, FL 32837

When?

Tuesday, February 14th, 2017

Intergruim

To learn more about Integrium, contact

Emily MacHale
Associate Director of Marketing & Research
emily.machale@integrium.com
908-375-2009

Learn more about Integrium


IntegriumExecutives will be in San Francisco during

J.P. Morgan 35th Annual Healthcare Conference 2017

Looking to expand your network in the biotech, medical device or
diagnostics field? Secure your spot to meet with us today!

What?

Integrium, LLC will be in San Francisco during J.P. Morgan 35th Annual Healthcare Conference and will be scheduling meetings with clients, friends and potential new relationships within the biotech, medical device and diagnostic sectors.

What-img-new

Where?

Parc 55 Hilton
55 Cyril Magnin St.
San Francisco, CA 94102

Where-img

When?

Monday, January 9th, 2017
8:30 AM - 3:30 PM PST
Wednesday, January 11th, 2017
8:30 AM - 4:00 PM PST

When-img

RSVP

Interested in meeting with Executives from Integrium, LLC? RSVP to receive private meeting time slots and details for the J.P. Morgan Conference today!

Learn More

To learn more about Integrium's services and expertise, visit us online!

Integrium is a full-service Clinical Proof of Concept (PoC) Firm focused within the therapeutic areas of Cardiovascular, Metabolic, Renal, Inflammatory, Dermatology, Wound Healing, Regenerative, and Orphan Disease.


Integrium, LLC
908-375-2009|714-541-5591
emily.machale@integrium.com
www.Integrium.com


Alternative Financing Solutions for Biotechnology

Complimentary breakfast and roundtable series

Date: Thursday, October 27th 2016

Time: 8:00 AM to 10:00 AM PST

Where: San Francisco, CA

{Location details to follow}

Join Integrium, LLC and our partners on October 27th to learn more about the growing biotechnology industry, strategic financing and raising capital to prepare for all steps in the clinical trial process, and the most powerful tools to get ahead in the life sciences field.

Learn more from our speakers on

  • How to raise capital from large strategic partners.
  • State of Life Sciences capital raising industry
  • Efficiently financing your biotech company through SBIR Grants, DOD Grants, NIH Funding, and more.
  • Four keys to a successful Proof of Concept (PoC) clinical trial.
  • Maximizing the pharmacoeconomic value of early phase compounds.

CLICK HERE TO REGISTER!

**If you are unable to view the link, please RSVP to Emily MacHale at
emily.machale@integrium.com


Integrium Clinical Research, LLC cordially invites you
to a Lunch and Learn

The Strategy Behind a Proof of Concept Clinical Trial:
Balancing Science, Logistics, Economics, and the FDA

  • Reducing Trial Risk while Maximizing the Pharmacoeconomic Value of an Early
    Phase Compound
  • How to Secure National Institutes of Health (NIH) Funding for a Proof of Concept Trial
  • The Keys to Underwriting a Proof of Concept Trial in Light of the Current Economic Environment
  • Structuring a Study Design and Protocol to Maximize the Post-Phase 2 Value of a Compound

About the Presenters

Dr. Joel Neutel


Medical Director, Integrium Clinical Research, LLC

Dr.Joel Neutel
  • Principal, Founder, and Medical Director of Integrium Clinical Research, Orange County Research Center, and Memorial Care Medical Research, with locations in California, New Jersey, and South Africa
  • Over 25 years of extensive experience in Proof of Concept clinical trials, serving the biopharmaceutical, Venture Capital, and Private Equity Industries
  • Conducted over 250 trials among 6,500 sites and 50,000 subjects; designated as a Specialist in Clinical Hypertension by ASH; and author of numerous publications in pharmacology and a member of several specialty organizations

Dr. Joana Rosario


Senior Medical Advisor, Whitemarsh Capital, LLC

Dr.Joel Neutel
  • Former Deputy Director at BSP, DAIDS, National Institutes of Health (NIH); and has facilitated hundreds of investigators access to funding through the NIH
  • Over 35 years of experience and internationally recognized as a researcher, educator, government official, and entrepreneur
  • Published over 50 peer-reviewed publications and received recognition awards from a list of prominent universities and organizations

Barbara A. Binzak Blumenfeld


Ph.D., Counsel, Buchanan Ingersoll & Rooney PC

Barbara A. Binzak Blumenfeld
  • Focuses her practice on clients whose products are subject to Food and Drug Administration (FDA) regulations, including drugs, foods, dietary supplements, medical foods, cosmetics, and medical devices.
  • Advises clients on numerous issues such as investigational new drug application (IND) and biologics license application (BLA) requirements for biologic products, such as stem cells.
  • Has co-authored a book chapter entitled Pioneer and Generic Drugs: Balance Between Product Life Cycle Extension and Anticompetitive Behavior.

About the Sponsors

Integrium Clinical Research, LLC


Integrium Clinicall Research, LLC
  • Integrium is a foundation of trusted advisors and clinical Proof of Concept experts across a range of therapeutic indications including cardiovascular, metabolic, regenerative medicine, and orphan compounds
  • Founded in 1998; 100+ employees with locations and Phase II-IV research clinics in California, New Jersey, and South Africa; 50+ bed PK Unit in California and 25+ bed PK Unit in New Jersey.
  • Access to 7000+ patients within varying disease states and 2500+ healthy volunteers in the US. In addition, access to 10,000+ patients within varying disease states in South Africa, with CRO partners in South Africa, Europe, Australia, and India.

Buchanan Ingersoll & Rooney


  • Founded in 1850 with 530+ attorneys in 18 offices across the U.S.
  • Buchanan is consistently ranked as a "powerhouse national law firm" by the National Law Journal, with its core service areas including: corporate and financial services; healthcare and pharmaceuticals; technology; and government relations, among others
  • Many of its attorneys have worked for the FDA, Congress or the DEA, as scientists or legal counsel

Whitemarsh Capital, LLC


  • Whitemarsh Capital has earned a reputation for successfully initiating, negotiating, structuring, and closing middle-market mergers, acquisitions, divestitures licensing and joint ventures.

Our Sponsors

Logo_Sponsors_03 Logo_Sponsors_07 Logo_Sponsors_07
Logo_Sponsors_07 Logo_Sponsors_07 Logo_Sponsors_07